Shengzhong Duan Selected Research

Neoplasms (Cancer)

1/2020	Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells.
10/2015	Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
3/2015	The neddylation-cullin 2-RBX1 E3 ligase axis targets tumor suppressor RhoB for degradation in liver cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shengzhong Duan Research Topics

Disease

3	Atherosclerosis 04/2024 - 09/2015
3	Neoplasms (Cancer) 01/2020 - 03/2015
2	Hypoxia (Hypoxemia) 03/2024 - 03/2015
2	Pulmonary Hypertension 03/2024 - 03/2015
2	Fibrosis (Cirrhosis) 11/2023 - 10/2016
2	Squamous Cell Carcinoma of Head and Neck 01/2022 - 01/2022
2	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2016
1	Vascular Calcification 04/2024
1	Chronic Renal Insufficiency 04/2024
1	Periodontitis 03/2024
1	Inflammation (Inflammations) 11/2023
1	Lung Injury 11/2023
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 11/2023
1	Colitis 03/2022
1	Myocardial Infarction 01/2022
1	Reperfusion Injury 01/2022
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022
1	Obesity 01/2021
1	Starvation 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 10/2015
1	Ischemia 07/2015
1	Carcinogenesis 03/2015
1	Liver Neoplasms (Liver Cancer) 03/2015
1	Adenoma (Adenomas) 01/2015
1	Colorectal Neoplasms (Colorectal Cancer) 01/2015
1	Polyps 01/2015

Drug/Important Bio-Agent (IBA)

2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2022
2	Proteins (Proteins, Gene)FDA Link 10/2016 - 10/2015
2	Cullin Proteins (Cullins)IBA 10/2015 - 03/2015
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 10/2015 - 03/2015
1	Member 3 Group A Nuclear Receptor Subfamily 4IBA 04/2024
1	Orphan Nuclear ReceptorsIBA 04/2024
1	hydroxide ionIBA 04/2024
1	apolipoprotein A-IV (apolipoprotein AIV)IBA 04/2024
1	Histones (Histone)IBA 04/2024
1	Neutralizing AntibodiesIBA 03/2024
1	Interferon-gamma (Interferon, gamma)IBA 03/2024
1	Retinoid X Receptor gammaIBA 11/2023
1	AlarminsIBA 11/2023
1	Small Interfering RNA (siRNA)IBA 11/2023
1	Liposomes (Liposome)IBA 11/2023
1	Interleukin-13IBA 11/2023
1	Therapeutic UsesIBA 03/2022
1	Dextran SulfateIBA 03/2022
1	Docetaxel (Taxotere)FDA Link 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2022
1	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2022
1	Topoisomerase InhibitorsIBA 01/2022
1	Nuclear Receptor Co-Repressor 1IBA 01/2022
1	fedratinibIBA 01/2022
1	Amino Acids FDA Link 01/2021
1	Leucine (L-Leucine)FDA Link 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	2,4-thiazolidinedione (thiazolidinedione)IBA 01/2020
1	alpha-galactosylceramideIBA 01/2020
1	Pioglitazone (Actos)FDA Link 01/2020
1	LipidsIBA 01/2020
1	Tamoxifen FDA LinkGeneric 12/2016
1	Apolipoproteins E (ApoE)IBA 12/2016
1	Fibronectins (Fibronectin)IBA 10/2016
1	Connective Tissue Growth FactorIBA 10/2016
1	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 10/2016
1	Eplerenone (Inspra)FDA LinkGeneric 10/2016
1	EnzymesIBA 10/2015
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 10/2015
1	pevonedistatIBA 10/2015
1	Glutathione (Reduced Glutathione)IBA 09/2015
1	oxidized low density lipoproteinIBA 09/2015
1	AntioxidantsIBA 09/2015
1	Interleukin-8 (Interleukin 8)IBA 07/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2015
1	CateninsIBA 07/2015
1	MonocrotalineIBA 03/2015
1	Protein Isoforms (Isoforms)IBA 03/2015
1	theasinensin AIBA 01/2015

Therapy/Procedure

3	Therapeutics 01/2022 - 03/2015
1	Lymph Node Excision (Lymph Node Dissection) 03/2024
1	Ligation 03/2024
1	Immunotherapy 01/2020